Amgen EVP Reese granted 12,063 company shares

REESE DAVID M reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

REESE DAVID M reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. executive David M. Reese, EVP & Chief Technology Officer, reported an equity award of 12,063 shares of common stock on March 3, 2026. The award was recorded at $0.00 per share, reflecting a grant rather than an open‑market purchase.

After this grant, Reese directly owned 47,650 Amgen common shares. This total includes 667 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which pay out in shares according to the vesting schedule.

Insider Trade Summary

Grant/Award: 12,063 shares

Grant/Award 1 txn

Insider REESE DAVID M

Role EVP & Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,063	$0.00	$0.00

Holdings After Transaction: Common Stock — 47,650 shares (Direct)

Footnotes (1)

1. F1. These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) EVP David M. Reese report in this Form 4 filing?

David M. Reese reported receiving an equity award of 12,063 Amgen common shares. The grant was recorded at $0.00 per share, indicating a compensation award rather than a market purchase, and increased his directly held Amgen common stock to a total of 47,650 shares.

How many Amgen (AMGN) shares does David M. Reese own after the reported transaction?

After the transaction, David M. Reese directly owns 47,650 Amgen common shares. This figure reflects his holdings following the 12,063‑share grant on March 3, 2026, and includes 667 Dividend Equivalents that are credited to his unvested restricted stock units.

What type of transaction is reported for Amgen (AMGN) executive David M. Reese?

The filing reports an acquisition via grant or award of common stock. Classified under transaction code “A,” it reflects a grant, award, or other acquisition of 12,063 non‑derivative Amgen common shares, not an open‑market buy or sell, and is held as direct ownership.

What are the 667 Dividend Equivalents mentioned in David M. Reese’s Amgen (AMGN) filing?

The 667 Dividend Equivalents are share-linked credits tied to Reese’s unvested RSUs. Granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan, they are paid out in Amgen common stock on a one‑to‑one basis according to the RSU vesting schedule.

Was cash paid for the 12,063 Amgen (AMGN) shares reported by David M. Reese?

No cash changed hands for these 12,063 shares. The transaction price per share is reported as $0.0000, indicating the shares were received as a grant or award of Amgen common stock, rather than purchased in the open market for cash consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 08:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REESE DAVID M

(Last) (First) (Middle)

ONE AMGEN CENTER

DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		12,063	A	$0	47,650(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ David M. Reese	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.